menu
    • menu

    Company profile for AgomAb Therapeutics N.V

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical ...
    AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.The AgomAb team has selected the most promising lead antibodies and continues to generate preclinical data that support the use of these antibodies in fibrotic, inflammatory, autoimmune and degenerative diseases. We are committed to advancing these molecules into clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AgomAb Therapeutics N.VBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Pieter Van Reysschootlaan 2/104 9051 Sint-Denijs-Westrem (Gent)
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://agomab.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Agomab Reports Positive Phase 2A Results For Ontunisertib
    Agomab Reports Positive Phase 2A Results For Ontunisertib

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3188799/0/en/Agomab-Announces-Positive-Topline-Phase-2a-Data-for-Ontunisertib-in-Fibrostenosing-Crohn-s-Disease.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Stenova Data at Digestive Disease Week 2025 Show AGMB-129 Potenti
    Stenova Data at Digestive Disease Week 2025 Show AGMB-129 Potenti

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3075467/0/en/Late-Breaking-Interim-STENOVA-Data-Presented-at-Digestive-Disease-Week-2025-Demonstrate-Potential-of-AGMB-129-in-Fibrostenosing-Crohn-s-Disease.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Stenova AGMB-129 data in Crohn’s at Digestive Disease Week® 2025
    Stenova AGMB-129 data in Crohn’s at Digestive Disease Week® 2025

    10 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250410135755/en/Late-Breaking-Interim-STENOVA-Data-for-AGMB-129-in-Fibrostenosing-Crohns-to-be-Presented-at-Digestive-Disease-Week-2025

    BUSINESSWIRE
    10 Apr 2025
    Share Share
    Agomab Reports Positive Ph 2a Data For AGMB-129 In Crohn’s Disease
    Agomab Reports Positive Ph 2a Data For AGMB-129 In Crohn’s Disease

    10 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250310274265/en

    BUSINESSWIRE
    10 Mar 2025
    Share Share
    Agomab Announces Appointment of Former Sandoz CFO
    Agomab Announces Appointment of Former Sandoz CFO

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118736621/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Agomab Secures $89 Million Series D For Fibrosis Pipeline
    Agomab Secures $89 Million Series D For Fibrosis Pipeline

    25 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024624593/en

    BUSINESSWIRE
    25 Oct 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search